Elevated SUA is increasingly recognized as a risk factor for kidney disease in adults with diabetes, yet there are limited data in youth. We hypothesized that elevated SUA would predict development of elevated UAE and HTN over time in teens with T2D. Serum creatinine, cystatin C, SUA, and urine albumin to creatinine ratio (ACR) were assessed in 539 youth, ages 12-17 with T2D duration <2 years at baseline in the TODAY study. Estimated GFR (eGFR) was calculated using creatinine and cystatin C. HTN was defined as systolic (SBP) or diastolic blood pressure (DBP) ≥130/80 mm Hg and elevated albumin excretion (UAE) as ACR ≥30mg/g. Mean arterial pressure (MAP) was calculated ([SBP + 2 (DBP)]/3). Generalized estimating equations and Cox proportional hazard models evaluated the relationship between SUA and outcome variables longitudinally over 7 years, adjusting for age, sex, race/ethnicity, BMI, A1c, eGFR, ACEi/ARB use, and TODAY treatment group assignment. Hyperuricemia (≥6.8 mg/dL) was present in 25.6%, HTN in 18.7%, and elevated UAE in 6.1% at baseline, and boys had higher baseline SUA than girls (6.7±1.4 vs. 5.4±1.2 mg/dl, p<0.0001). Over 7 years, 37.4% developed HTN and 18.0% elevated UAE. Baseline SUA correlated with increase in SBP (β±SE: 0.66±0.16, p<.0001), DBP (0.37±0.15, p=0.01), MAP (0.47±0.14, p=0.001), and log UAE (0.05±0.02, p=0.01) over time in multivariable models. Higher baseline SUA increased risk of incident HTN (HR: 1.20, 95% CI 1.05-1.36, p=0.007, per 1 mg/dL increase in SUA) and incident elevated UAE (HR: 1.23, 95% CI 1.03-1.47, p=0.02, per 1 mg/dL increase in SUA) in fully adjusted models. Hyperuricemia was common in youth with T2D; higher baseline SUA independently increased risk for onset of HTN and elevated UAE over 7 years. Therapies lowering SUA may hold promise to impede development of diabetic kidney disease and HTN in T2D youth.


P. Bjornstad: Consultant; Self; Boehringer Ingelheim GmbH. L.M. Laffel: Consultant; Self; Eli Lilly and Company, Novo Nordisk Inc., Sanofi US, MannKind Corporation, Roche Diagnostics Corporation, Dexcom, Inc., Insulet Corporation, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Johnson & Johnson Diabetes Institute, LLC. J.L. Lynch: Other Relationship; Self; Novo Nordisk Inc.. Research Support; Self; Daiichi Sankyo Company, Limited. L. El Ghormli: None. R.S. Weinstock: Research Support; Self; Medtronic MiniMed, Inc., Mylan, Kowa Pharmaceuticals America, Inc., Diasome Pharmaceuticals, Inc., Calibra Medical, Dexcom, Inc., Ultradian Diagnostics LLC., JAEB Center For Health Research, JDRF, National Institute of Diabetes and Digestive and Kidney Diseases. S.E. Tollefsen: None. K.J. Nadeau: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.